Minerva Neurosciences
Psychiatric and neurological therapeutics targeting CNS receptors
Follows are private to you and power your alerts
Updated · minervaneurosciences.com
- Sector
- Biotech
- Headquarters
- Burlington, MA
- Latest Form D
- $20M offered, Jul 2023
- Total capital
- $32M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $32M
- 3 Form D · last Jul 2023
- 40 months since last filing
- Federal contracts
- $5K
- 1 award · Health and Human S
- Rank in Biotech#390 of 4373
- Granted patents
- 9
- 31 pending · first 2016
- Rank in peer group#179 of 1449
Capital timeline
Latest events
- Offering registeredForm D · SEC · 3rd filing$20M
- Private capital raisedForm D · SEC · 2nd filing$1M
- Federal contractHealth and Human S · Igf::ot::igf Minerva BIOTECHNOLOGIES:1185680 [15-004428]$5K
- Private capital raisedForm D · SEC · 1st filing$31M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#179 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Remy LuthringerResearcherExecutive Officer, DirectorLinked by 1 patent
- David Peter KupferDirectorNamed in SEC Form D filings
- Fouzia Peter Laghrissi-ThodeDirectorNamed in SEC Form D filings
- Francesco De RubertisDirectorNamed in SEC Form D filings
- Fred AhlholmExecutive OfficerNamed in SEC Form D filings
- Frederick AhlholmExecutive OfficerNamed in SEC Form D filings
Show all 16 people
- Geoff RaceExecutive OfficerNamed in SEC Form D filings
- Geoffrey RaceExecutive OfficerNamed in SEC Form D filings
- Hans Peter HaslerDirectorNamed in SEC Form D filings
- Jan Van HeekDirectorNamed in SEC Form D filings
- Jeryl Peter HillemanDirectorNamed in SEC Form D filings
- Joseph ReillyExecutive OfficerNamed in SEC Form D filings
- Marc BeerDirectorNamed in SEC Form D filings
- Mark LevineExecutive OfficerNamed in SEC Form D filings
- Michele OllierDirectorNamed in SEC Form D filings
- Nico VandervelpenDirectorNamed in SEC Form D filings
What it has protected
USPTO · 9 granted of 40- PendingUse Of Roluperidone To Treat Negative Symptoms And Disorders, Increase Neuroplasticity, And Promote NeuroprotectionUSPTOApplication 19021817
- PendingMethods Of Use Of Cyclic Amide Derivatives To Treat Sigma Receptor Mediated DisordersUSPTOApplication 19021774
- Pending(2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL Or Its Metabolite For Treating Anxiety DisordersUSPTOApplication 19021709
Show all 40 patent records
- Use Of Roluperidone To Treat Negative Symptoms And Disorders, Increase Neuroplasticity, And Promote NeuroprotectionJul 24, 2025 · Application 19021817Pending
- Methods Of Use Of Cyclic Amide Derivatives To Treat Sigma Receptor Mediated DisordersJul 17, 2025 · Application 19021774Pending
- (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL Or Its Metabolite For Treating Anxiety DisordersJul 17, 2025 · Application 19021709Pending
- Compositions And Methods For Treating SchizophreniaJun 19, 2025 · Application 18961748Pending
- Methods Of Use Of Cyclic Amide Derivatives To Treat SchizophreniaJun 5, 2025 · Application 18821656Pending
- Methods Of Use Of Phenoxypropylamine Compounds To Treat DepressionApr 3, 2025 · Application 18764714Pending
- Gastro-resistant Controlled Release Oral Dosage FormsJan 9, 2025 · Application 18738782Pending
- Sigma Ligand Compounds And Uses ThereofNov 14, 2024 · Application 18647374Pending
- Gastro-resistant Controlled Release Oral Dosage FormsJul 30, 2024 · US 12,048,768Granted
- Sigma Ligand Compounds And Uses ThereofJun 11, 2024 · US 12,006,300Granted
- Methods Of Using A Phenoxypropylamine Compound To Treat PainJan 18, 2024 · Application 18351682Pending
- Methods Of Using A Phenoxypropylamine Compound To Treat PainSep 26, 2023 · US 11,766,430Granted
- Use Of Roluperidone In Preventing Relapse In Schizophrenia PatientsAug 17, 2023 · Application 18168028Pending
- (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL Or Its Metabolite For Treating Anxiety DisordersAug 10, 2023 · Application 18302691Pending
- Compositions And Methods For Treating SchizophreniaJun 29, 2023 · Application 18111072Pending
- Compositions And Methods For Treating Negative Symptoms In Non-schizophrenic PatientsJun 22, 2023 · Application 17825783Pending
- Gastro-resistant Controlled Release Oral Dosage FormsOct 11, 2022 · US 11,464,744Granted
- Methods Of Use Of Cyclic Amide Derivatives To Treat SchizophreniaSep 1, 2022 · Application 17745024Pending
- Use Of Roluperidone To Treat Negative Symptoms And Disorders, Increase Neuroplasticity, And Promote NeuroprotectionMar 31, 2022 · Application 17366310Pending
- Use Of Roluperidone To Treat Negative Symptoms And Disorders, Increase Neuroplasticity, And Promote NeuroprotectionAug 10, 2021 · US 11,083,723Granted
- Compositions And Methods For Treating SchizophreniaJul 29, 2021 · Application 17017816Pending
- Methods Of Use Of Cyclic Amide Derivatives To Treat Sigma Receptor Mediated DisordersApr 15, 2021 · Application 16914862Pending
- Compositions And Methods For Treating SchizophreniaOct 13, 2020 · US 10,799,493Granted
- Methods Of Use Of Phenoxypropylamine Compounds To Treat DepressionJul 16, 2020 · Application 16829657Pending
- Compositions And Methods For Treating Negative Symptoms In Non-schizophrenic PatientsJul 18, 2019 · Application 16302722Pending
- (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL Or Its Metabolite For Treating Anxiety DisordersJun 20, 2019 · Application 16302730Pending
- Compositions And Methods For Treating SchizophreniaApr 16, 2019 · US 10,258,614Granted
- Methods Of Use Of Cyclic Amide Derivatives To Treat SchizophreniaJun 7, 2018 · Application 15656062Pending
- Compositions And Methods For Treating SchizophreniaAug 15, 2017 · US 9,730,920Granted
- Methods Of Use Of Cyclic Amide Derivatives To Treat Sigma Receptor Mediated DisordersDec 8, 2016 · Application 15163385Pending
- Compositions And Methods For Treating SchizophreniaOct 4, 2016 · US 9,458,130Granted
- Methods Of Use Of Phenoxypropylamine Compounds To Treat DepressionJul 24, 2014 · Application 14163827Pending
- Use Of Condensed Azacycle Compounds For The Treatment Of Lysosomal Storage DisordersApplication 63485449Pending
- Use Of Roluperidone (MIN-101) To Treat Negative Symptoms Of Neurodegenerative Disorders And To Enhance Brain-derived Neurotrophic Factor (bdnf) Release By Astrocytes And Hippocampal NeuronsApplication 62831535Pending
- Use Of Roluperidone For The Treatment Of Lysosomal Storage DisordersApplication 63592675Pending
- Use Of Condensed Azacycle Compounds For The Treatment Of Lysosomal Storage DisordersApplication 19157045Pending
- Use Of Condensed Azacycle Compounds For The Treatment Of Lysosomal Storage DisordersApplication PCTUS2024016048Pending
- Methods Of Using A Phenoxypropylamine Compound To Treat PainApplication 62726800Pending
- Use Of Roluperidone (MIN-101) To Treat Negative Symptoms Of Neurodegenerative Disorders And To Enhance Brain-derived Neurotrophic Factor (bndf) Release By Astrocytes And Hippocampal NeuronsApplication 62720667Pending
- Gastro-resistant Controlled Release Oral Dosage FormsApplication PCTUS2018038853Pending
Related companies, and why
- RADIOMEDIX, INC.Similar federal contract value in Biotech · $5K in contracts
- STEALTH BIOLOGICS LLCSimilar federal contract value in Biotech · $5K in contracts
- Claret Bioscience LLCSimilar federal contract value in Biotech · $5K in contracts
- Foresite LabsSimilar federal contract value in Biotech · $3K in contracts
- Veloxis PharmaceuticalsSimilar federal contract value in Biotech · $83 in contracts
- CRISPRQC INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .